Cite

HARVARD Citation

    Cousin, S. et al. (2022). Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. European journal of cancer. pp. 161-169. [Online]. 
  
Back to record